Earnings ·
ANI Pharmaceuticals reported second quarter 2026 financial results with total net revenues of $266.0 million, a 25.9%…
ANIPAni Pharmaceuticals Inc
ANI Pharmaceuticals reported second quarter 2026 financial results with total net revenues of $266.0 million, a 25.9% increase year-over-year. Rare Disease segment revenues rose 30.7% to $135.8 million, driven by a 43.5% surge in Cortrophin Gel sales to $117.1 million and the operational launch of its gout expansion sales force. Generics revenues grew 9.7% to $99.1 million. The company reported GAAP net income of $24.7 million, or $1.05 per diluted share, compared to $8.1 million in the prior year period. Adjusted non-GAAP EBITDA increased 32.4% to $71.6 million. Management reaffirmed full-year 2026 guidance for total net revenue of $1,080-$1,140 million and adjusted non-GAAP EBITDA of $285-$300 million, while modestly lowering Cortrophin Gel guidance to $520-$540 million. The board authorized a share repurchase program for up to $100.0 million through May 2029. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and commercializing therapeutics in rare diseases, generics, and branded products.